Dexcom (DXCM) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Dexcom (DXCM) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.94 Bn | 194.34 Bn | 7.27 Bn | -12.28% |
| 2 | Stryker | 129.96 Bn | 126.49 Bn | 4.50 Bn | 20.02% |
| 3 | Medtronic | 120.01 Bn | 110.79 Bn | 6.41 Bn | 1.93% |
| 4 | Boston Scientific | 74.08 Bn | 73.54 Bn | 3.85 Bn | 51.47% |
| 5 | Edwards Lifesciences | 52.66 Bn | 48.40 Bn | 1.35 Bn | -7.83% |
| 6 | Dexcom | 34.63 Bn | 32.68 Bn | 830.00 Mn | 29.05% |
| 7 | GE HealthCare Technologies | 34.02 Bn | 31.91 Bn | 2.18 Bn | 11.15% |
| 8 | Koninklijke Philips | 26.43 Bn | 23.11 Bn | 4.55 Bn | 1,825.47% |
| 9 | Steris | 23.18 Bn | 22.69 Bn | 684.20 Mn | 17.54% |
| 10 | Zimmer Biomet Holdings | 19.36 Bn | 18.95 Bn | 1.54 Bn | -1.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.05% |
| Mar 31, 2026 | 60.12% |
| Dec 31, 2025 | 42.80% |
| Sep 30, 2025 | 41.02% |
| Jun 30, 2025 | 52.30% |
| Mar 31, 2025 | 2.70% |
| Dec 31, 2024 | 212.86% |
| Sep 30, 2024 | 15.53% |
| Jun 30, 2024 | 22.32% |
| Mar 31, 2024 | 37.35% |
| Dec 31, 2023 | -14.59% |
| Sep 30, 2023 | 18.68% |
| Jun 30, 2023 | 35.78% |
| Mar 31, 2023 | 34.67% |
| Dec 31, 2022 | -0.32% |
| Sep 30, 2022 | 30.25% |
| Jun 30, 2022 | 89.89% |
| Mar 31, 2022 | 77.76% |
| Dec 31, 2021 | 69.10% |
| Sep 30, 2021 | 23.28% |